Epidemiologic Field Studies

BCDDP：乳腺癌检测示范项目跟踪研究(1030)这项研究跟踪了乳腺癌示范项目(BCDDP)的约60,000名前参与者。目前的分析包括：1)子宫切除情况以及所有原因和特定原因的死亡率；2)涉及乳腺癌、结肠癌、卵巢癌和肾癌的饮食汇集项目分析；以及3)大量DCEG队列汇集项目。(4)在中国农村进行的为期8年的试验结束后，我们收集了额外的7年的随访数据，以确定三种治疗方法中的任何一种是否会影响胃癌的发病率或特定的死亡原因。这些治疗是从1995年到2003年长期补充维生素C、E和硒和大蒜，并于1995年一次性给予阿莫西林/奥美拉唑。一篇正在修订的论文显示，阿莫西林/奥美拉唑治疗在14年期间降低了胃癌的发病率。炎症性乳腺癌(IBC)试点研究和病例对照研究(314)这项病例对照研究将包括北非4个中心(突尼斯1个中心加上几个私人诊所、埃及2个和摩洛哥2个)在五年期间累积的大约400个IBC病例。两个对照组包括：1)400例非IBC乳腺癌病例；2)400名来访者对照(不包括一级亲属)，随机选择在研究医院住院的女性患者(不包括患有乳腺癌、卵巢癌、子宫内膜癌和鼻咽癌的患者)。这项研究包括管理问卷、人体测量、唾液/颊细胞收集、IBC病例乳房的数字照片，以及在选定中心收集IBC病例和非IBC乳腺癌对照的石蜡包埋肿瘤组织。这项研究是与密歇根大学联合进行的，表格的开发和翻译由美国国家癌症研究所协调。NCI-DCEG负责在埃及、突尼斯和摩洛哥的研究中心制定研究程序。数据收集工作分别于2009年3月在埃及、2009年8月在突尼斯和2011年1月在摩洛哥开始。

BCDDP: Breast cancer detection demonstration project follow-up study (1030) This study follows about 60,000 former participants in the Breast Cancer Demonstration Project (BCDDP). Current analyses include: 1) hysterectomy status and all-cause and cause-specific mortality; 2) dietary pooling project analyses involving cancers of the breast, colon, ovary, and kidney; and 3) numerous DCEG cohort pooling projects. Gastric cancer: Randomized multi-intervention trial to inhibit precancerous gastric lesions in Linqu, Shandong Province (446) We gathered additional follow-up data for seven years following the end of an 8-year trial in rural China to determine whether any of three treatments would affect gastric cancer incidence or specific causes of mortality. The treatments were long-term vitamin (C, E, and selenium) supplementation and garlic supplementation, given from 1995 to 2003, and one time administration of amoxicillin/omeprazole given in 1995. A paper is in revision showing that amoxicillin/omeprazole treatment reduced gastric cancer incidence over a fourteen year period. Inflammatory breast cancer (IBC) pilot study and case-control study (314) This case-control study will include approximately 400 IBC cases accrued over a five-year period at 4 centers in North Africa (1 center in Tunisia plus several private clinics, 2 in Egypt, and 2 in Morocco). Two control groups are being included: 1) 400 non-IBC breast cancer cases and; 2) 400 visitor controls (excluding first-degree relatives) to randomly selected female inpatients (excluding those with breast, ovarian, endometrial, and nasopharyngeal cancer) in the study hospitals. The study involves the administration of a questionnaire, anthropometric measurements, Saliva/Buccal Cells collection, digital photographs of the breasts of IBC cases, and the collection of paraffin-embedded tumor tissue for IBC cases and non-IBC breast cancer controls at selected centers. The study is being conducted as a consortium with the University of Michigan, with forms development and translation coordinated at the National Cancer Institute-USA. The NCI-DCEG is responsible for developing study procedures at the study centers in Egypt, Tunisia, and Morocco. Data collection began in March 2009 in Egypt, August 2009 in Tunisia, and January 2011 in Morocco.